About Eikonizo
Eikonizo is a company based in Cambridge (United States) founded in 2017 by Janice Kranz, Al Schroeder, and William Shaw. Eikonizo has raised $2.37 million across 6 funding rounds from investors including Novo Nordisk and HHS. The company has 7 employees as of December 31, 2024. Eikonizo offers products and services including HDAC6 Inhibitors. Eikonizo operates in a competitive market with competitors including T3D Therapeutics, Longeveron, Alchemab, Alzheon and AlphaCognition, among others.
- Headquarter Cambridge, United States
- Employees 7 as on 31 Dec, 2024
- Founders Janice Kranz, Al Schroeder, William Shaw
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Eikonizo Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.37 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
Novo Nordisk
& 1 more
-
Employee Count
7
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eikonizo
Eikonizo offers a comprehensive portfolio of products and services, including HDAC6 Inhibitors.
Small molecules that inhibit HDAC6 to improve transport and reduce aggregates in diseases
People of Eikonizo
Unlock access to complete
Unlock access to complete
Funding Insights of Eikonizo
Eikonizo has successfully raised a total of $2.37M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eikonizo
Eikonizo has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Novo Nordisk and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Eikonizo
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eikonizo
Investment portfolio details for Eikonizo
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eikonizo
Detailed financials for Eikonizo
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eikonizo Comparisons
Peer comparison for Eikonizo
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eikonizo
Eikonizo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as T3D Therapeutics, Longeveron, Alchemab, Alzheon and AlphaCognition, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative diseases, including Alzheimer's, are developed.
|
|
| Locked | Locked | Locked |
Cellular therapies for aging-related and life-threatening conditions are developed.
|
|
| Locked | Locked | Locked |
Developer of antibody based therapeutics to treat cancers, neurodegenerative conditions and infectious diseases
|
|
| Locked | Locked | Locked |
Oral inhibitors of amyloid aggregation for Alzheimer's treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for brain and spinal cord diseases are developed.
|
|
| Locked | Locked | Locked |
Medical foods and drugs for Alzheimer's disease are developed.
|
Detailed competitors of Eikonizo
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eikonizo
Complete news archive for Eikonizo
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eikonizo
Eikonizo was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Eikonizo is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Janice Kranz is the current CEO of Eikonizo. They have also founded this company.
Eikonizo is a funded company, having raised a total of $2.37M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Eikonizo is 7.
Eikonizo was founded in 2017 in Cambridge, United States, and focuses on the biotechnology sector. Small molecule therapeutics that penetrate the brain are developed to address neurodegenerative diseases. The lead program targets selective histone deacetylase 6 (HDAC6) inhibitors for conditions such as Alzheimers disease and amyotrophic lateral sclerosis. Operations center on advancing these inhibitors through research and development stages.
Eikonizo's top competitors include Alzheon, Longeveron and Alchemab.
Eikonizo offers HDAC6 Inhibitors.
Eikonizo has 2 investors. Key investors include Novo Nordisk, and HHS.